Anti-HIV type 1 activity of wild-type and functional defective RANTES intrakine in primary human lymphocytes.
We have developed a genetic "intrakine" strategy to inactivate the CC-chemokine receptor 5 (CCR-5), the principal coreceptor for macrophage (M)-tropic HIV-1 viruses (Yang et al, 1997). The inactivation of CCR5 was achieved by targeting a modified CC-chemokine (RANTES) to the lumen of the endoplasmic reticulum (ER) to block the transport of the newly synthesized CCR-5. The transduced lymphocytes with the phenotypic CCR5 knockout were shown to be resistant to M-tropic HIV-1 infection. This study illustrated the feasibility of the intrakine strategy to block HIV-1 infection. In our current study, the potential clinical application of the intrakine approach was further evaluated in human peripheral blood lymphocytes (PBLs). PBLs were transduced with the RANTES intrakine gene by using retroviral vectors with the truncated low-affinity human nerve growth factor receptor (deltaNGFR) marker, and then isolated by an anti-NGFR antibody/magnetic bead method. The surface expression of CCR-5 in the transduced lymphocytes was dramatically inhibited, as demonstrated by flow cytometric assays. The transduced PBLs were shown to resist various types of M-tropic HIV-1 virus infection. The cell viability, cell proliferation rates, and cell surface markers of the intrakine-transduced PBLs were shown to be comparable to those of control PBLs. The transduced PBLs were also found to respond to the stimulation of various CXC- and CC-chemokines, other than RANTES. The transduced PBLs responded to tetanus antigen stimulation by increasing IL-2 production and cell proliferation. In addition, a functionally defective mutant of RANTES that retains its binding activity to CCR-5, but loses its signaling ability, was used to generate a mutant RANTES intrakine. The primary lymphocytes transduced with the mutant RANTES intrakine were found to be resistant to M-tropic HIV-1 infection. From these results, we conclude that the primary human lymphocytes transduced with either the wild-type or functionally defective RANTES intrakine are resistant to M-tropic HIV-1 infection, and maintain their basic biological functions. This study, therefore, indicates the potential clinical application of the intrakine approach for HIV-1 gene therapy.
Yang
A G
AG
Department of Cancer Biology, Comprehensive Cancer Center, Wake Forest University School of Medicine, Winston-Salem, NC 27157, USA.
Zhang
X
X
Torti
F
F
Chen
S Y
SY
D000954:Antigens, Surface / Q000235:genetics; D065100:CCR5 Receptor Antagonists; D054407:Chemokine CCL4; D018946:Chemokine CCL5 / Q000235:genetics*; D018925:Chemokines / Q000235:genetics; D002633:Chemotaxis / Q000502:physiology; D004721:Endoplasmic Reticulum / Q000378:metabolism; D005434:Flow Cytometry; D015316:Genetic Therapy / Q000379:methods; D005822:Genetic Vectors / Q000235:genetics; D015658:HIV Infections / Q000235:genetics / Q000628:therapy; D006801:Humans; D007376:Interleukin-2 / Q000378:metabolism; D008214:Lymphocytes / Q000821:virology*; D019402:Macrophage Inflammatory Proteins / Q000235:genetics; D015728:Receptors, HIV / Q000037:antagonists & inhibitors*; D015682:Retroviridae Proteins, Oncogenic / Q000032:analysis; D013744:Tetanus Toxin / Q000494:pharmacology; D014161:Transduction, Genetic / Q000235:genetics
D000954:Antigens, Surface; D065100:CCR5 Receptor Antagonists; D054407:Chemokine CCL4; D018946:Chemokine CCL5; D018925:Chemokines; D007376:Interleukin-2; D019402:Macrophage Inflammatory Proteins; D015728:Receptors, HIV; D015682:Retroviridae Proteins, Oncogenic; D013744:Tetanus Toxin; C060954:p24 protein, Human T-lymphotropic virus 1